KCL leads first guidelines on immune monitoring for hard-to-treat blood cancer
Myelodysplastic syndromes are a group of blood cancers that currently affect more than 7,000 people in the UK
Read More
Tag: myelodysplastic syndromes
EC clears new class of anaemia therapy
BMS’ Reblozyl is the first and only erythroid maturation agent approved in the EU
Read More
BI drug gets orphan status for MDS
Boehringer Ingelheim has bagged US orphan drug designation for its anti-CD33 monoclonal antibody BI 836858 for the treatment of myelodysplastic syndromes (MDS).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
